Lymphoma (iNHL): A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's
Can modification of vitamin D levels in the blood, through supplementation, improve
outcomes in patients with indolent lymphoma treated with rituximab?
Basic Study Information
Purpose:Location: Cancer Center
If you decide and are eligible to take part in this study, in addition to the standard
treatment, rituximab, you will be randomized to receive an oral dose of either 2,000
IU vitamin D (also called cholecalciferol) supplementation or placebo. The randomization
will be 2:1. A 2:1 randomization means for every three people enrolled on the study,
people will receive vitamin D and one person will receive placebo. This study is conducted
in a double blind fashion, which means neither you nor your doctor will know which
treatment group you are in.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03078855?term=ilyad&rank=1
Study Reference #: ULYM17025
Lead Researcher (Principal Investigator)
Jonathan Friedberg, MD
Study Contact InformationStudy Coordinator: Par Ranjbar
Phone: (585) 275-3817
Additional Study Details
Learn More About These Conditions
More information about Lymphoma
Trial Not Found
The study you are looking for is not active at this time.
Return to Search